Penumbra could generate healthy sales and earnings growth, gaining market share in MT. MT’s share would rise to around 50% in DVT and about 60% in PE. Don’t miss this list of 3 high-yield ...

Penumbra, Inc. (NYSE:PEN) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. The company announced the completion of enrollment in STORM-PE clinical trial. The pivotal, ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% ...

Penumbra is Friday's IBD Stock Of The Day following a strong third-quarter report and a "landmark" study vs. blood thinners.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min At Penumbra Inc. Shruthi Narayan ...

Campaign is led by prominent medical societies to minimize discrepancies in treating blood clot conditions, such as in pulmonary embolism, where there are often delays in care (up to 26% of patients ...

"This is an important milestone that underscores Penumbra's commitment to transforming care for patients with pulmonary embolism," said James F. Benenati, MD, FSIR, chief medical officer at Penumbra. ...

Survey Conducted by the Get Out the Clot Campaign, an Initiative Focused on Identifying and Closing Gaps in Patient Care for Blood Clots ALAMEDA, Calif., Sept. 9, 2025 /PRNewswire/ -- The American ...